NASDAQ:EVFM Evofem Biosciences (EVFM) Stock Price, News & Analysis $0.0091 0.00 (-2.15%) As of 08/1/2025 03:37 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evofem Biosciences Stock (NASDAQ:EVFM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evofem Biosciences alerts:Sign Up Key Stats Today's Range$0.0090▼$0.009650-Day Range$0.0086▼$0.0152-Week Range$0.0061▼$0.0150Volume389,398 shsAverage Volume416,746 shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. Read More Evofem Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreEVFM MarketRank™: Evofem Biosciences scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evofem Biosciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evofem Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evofem Biosciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the outstanding shares of Evofem Biosciences have been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently increased by 330.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvofem Biosciences does not currently pay a dividend.Dividend GrowthEvofem Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.90 Percentage of Shares Shorted0.10% of the outstanding shares of Evofem Biosciences have been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently increased by 330.42%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Evofem Biosciences this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evofem Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of Evofem Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.22% of the stock of Evofem Biosciences is held by institutions.Read more about Evofem Biosciences' insider trading history. Receive EVFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EVFM Stock News HeadlinesPhexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary MommyJuly 15, 2025 | finance.yahoo.comEvofem Biosciences, Inc. (EVFM) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)Windtree Contracts Chinese Firm to Make Evofem's ContraceptiveJune 26, 2025 | marketwatch.comEvofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug StoreJune 23, 2025 | prnewswire.comEvofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of DirectorsJune 9, 2025 | businesswire.comEvofem Signs SOLOSEC License Agreement for Middle East with Pharma 1May 21, 2025 | prnewswire.comEvofem Biosciences Inc. Q1 Earnings SummaryMay 17, 2025 | nasdaq.comSee More Headlines EVFM Stock Analysis - Frequently Asked Questions How have EVFM shares performed this year? Evofem Biosciences' stock was trading at $0.0099 at the beginning of 2025. Since then, EVFM shares have decreased by 8.1% and is now trading at $0.0091. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences, Inc. (NASDAQ:EVFM) announced its earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%. When did Evofem Biosciences' stock split? Shares of Evofem Biosciences reverse split on the morning of Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Evofem Biosciences? Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F). Company Calendar Last Earnings6/16/2023Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVFM CIK1618835 Webwww.evofem.com Phone(858) 550-1900Fax844-828-2010Employees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.98 million Net Margins-46.42% Pretax Margin-46.42% Return on Equity-91.97% Return on Assets-61.93% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.09 Sales & Book Value Annual Sales$11.39 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value($2.64) per share Price / Book0.00Miscellaneous Outstanding Shares118,656,000Free Float113,118,000Market Cap$1.08 million OptionableNot Optionable Beta-0.92 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:EVFM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.